Imagion Biosystems Limited (ASX: IBX) has lodged “Appendix 3B: New issue announcement, application for quotation of additional securities and agreement” with the Australian Securities Exchange.View “Appendix 3B: New issue announcement”
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)